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OBJECTIVES: A new drug application authorized generic (AG) has the same active 
and inactive ingredients as the brand and it is marketed under a different labeler 
code, product code, trade name, trademark, or packaging (other than repackag-
ing) than the brand. Authorized generics compete in price with generic drugs. 
We assessed trends in the marketing of authorized generics in the US in the 
period 1982-November 2014. METHODS: Data were derived from the FDA data-
bases: “Database for Authorized Generic Drugs,” National Drug Code, Online Label 
Repository, and Approved Drug Products with Therapeutic Equivalence Evaluations. 
Time trends in generic marketing were described and compared with chi-square 
tests. RESULTS: In November 2014, the FDA listed 2301 approved active ingredients 
and combinations, with 3686 route/dosage forms and 7932 strengths. There were 296 
generic drugs approved before 1982, 195 in 1982-1989, 140 in the 1990s, 285 in the 
2000s, and 175 in 2010-Nov 2014. By November 2014, 47.4% of FDA approved active 
ingredients and combinations had generic competition, 22.00% were discontinued 
without generic competition, 10.8% did not have patent or exclusivity protection 
and did not have generic competition, and 19.7% were under patent or exclusivity 
protection. A total of 36.4% of the active ingredients/combinations with generic 
competition had at least one AG. AGs were marketed for 29% of the route/dosage 
forms and 27.4% of the strengths with generic competition. The percentage of active 
ingredients/combinations with generic competition and AG significantly increased 
from 15.5% before 1982, to 28.2% in 1982-1989, 47.1% in the 1990s, and 54.6% in the 
2000s, and 38.9% in 2010-Sep 2014 (p< 0.05). CONCLUSIONS: A significant percent-
age of generic drugs experienced the entrance of an authorized generic. The use of 
authorized generics increased overtime. The effect of authorized generics on the 
generic market and the incentives for generic entry should be assessed.
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OBJECTIVES: To assess the perception of health sciences students of southern 
Karnataka towards generic drugs. METHODS: The study was performed over a 
period of one month through one to one structured surveys with a random sample 
of 200. The response was analyzed by descriptive and frequency statistics using 
SPSS ver. 20. RESULTS: Out of the 200 questionnaires administered 183 responded 
with response rate of 91.50% and mean age of 23.64 ± 3.20. Out of total respond-
ents 47 % were undergraduates and 45.4% were postgraduates. 54.6 % students 
were from medical sciences followed by 23 % from allied health sciences and 9.8 % 
from pharmaceutical sciences. The knowledge was assessed and 34.5 % agreed that 
brand name drugs are of better quality than generic drugs while 38.3 % disagreed. 
40.5% disagreed that brand name drugs were more effective than generic medicines 
and 32.1 % were unsure. 44.2 % students disagreed that generic drugs have more 
side effects than brand name drugs while 15.3 % agreed. Finally 71.1% agreed that 
generic drugs were less expensive than brand name drugs. Attitude towards the 
generic drugs was also assessed. Prescribing generic drugs will reduce the treat-
ment cost and cost related non-compliance was agreed upon by 74.9 % and 78.7 
% students respectively. 81.4% agreed that increased use of generic medicine will 
reduce unethical marketing practices by Pharmaceutical companies. 80.8 % agreed 
that more policies should be framed to promote generics prescriptions and 85.3 % 
believed that the community pharmacist can play important role to promote the 
use. CONCLUSIONS: In a country like India where brand name drugs have an upper 
hand the attitude of younger breed of professionals is encouraging but on a contrast 
the knowledge was low and many resorted to be unsure on various basic aspects.
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OBJECTIVES: Since the increasing threat of community-associated resistant organ-
isms, emphasis has been placed on increasing education and awareness for clini-
cians and the public regarding appropriate antibiotic use and antibiotic resistance 
through community-based initiatives. Teachers and students are a significant group 
as they can influence the society effectively. This qualitative study was undertaken 
to find out their perception and knowledge about antibiotic use, antimicrobial 
resistance (AMR) and suggestions for practical interventions for rational use of 
antibiotics. METHODS: Focus group discussions (FGDs) with high school students 
and teachers were conducted in five municipal wards of Delhi in five schools (2 
private and 3 public). Data on antibiotic knowledge, resistance, and behaviors with 
respect to antibiotics use were collected. Students were also asked to answer four 
basic questions on antibiotic knowledge. The FGDs (n= 5 for each group; teach-
ers= 4-8 and students= 15-22 participants/FGD) were analyzed using ‘thematic 
analysis’. RESULTS: Students had extremely poor knowledge regarding antibiot-
ics and antimicrobial resistance, while only some teachers had a very rudimen-
tary understanding. Four broad themes needing attention emerged during FGDs: 
definition of antibiotic; usage of antibiotics in different conditions, including fever 
and diarrhea; role of doctors in informing patients about antibiotic usage; inter-
ventions and strategies for rational use of antibiotics. These results were further 
divided into various sub-themes depending upon responses of each group. In order 
to tackle these problems, both groups suggested a multi-pronged approach includ-
ing, robust awareness campaigns, better doctor-patient relationships and stronger 
regulations. CONCLUSIONS: Though high school students and teachers in Delhi 
showed poor awareness about antibiotic use and resistance, they exhibited a keen 
interest in learning about these issues. Their awareness levels can be targeted using 
health communication methods to shape correct perceptions about antibiotic use, 
containment of AMR and thus preservation of antibiotics for future generations.
to a national random sample of hospitals stratified by number of hospitals per state. 
Pharmacy directors’ opinions on CDTM were assessed using four scales: Perceived 
Support for CDTM, Financial Impact on Pharmacy, Strategic Impact on Pharmacy 
and Effect of Regulations on CDTM. Respondents rated items on a 5-point Likert 
scale where 1= strongly disagree, 2= disagree, 3= neutral, 4= agree, and 5= strongly 
agree. Scales were scored so higher scores represented more positive perceptions 
of CDTM. Possible scores ranged from 1-5. Means and standard deviations were 
calculated for each scale. ANOVA compared current scale scores to scale scores 
reported in 2003. Two open-ended questions asked respondents to identify barriers 
and facilitators to CDTM. Content analysis identified common themes. RESULTS: 
1,024 surveys were mailed. 70 were returned undeliverable. 7 were returned incom-
plete, yielding 286 usable surveys from 947 assumed delivered (30.2 percent). Based 
on mean±standard deviation scale scores, respondents perceived CDTM had good 
support (3.9±0.4), positive strategic impact (3.8±0.5), little or no financial impact on 
pharmacy (2.9±0.8), and were neutral regarding CDTM regulations (2.7±0.7). No sig-
nificant difference was seen in any mean scale score as compared to 2003 (p> 0.05). 
Physician support was the most often mentioned facilitator of CDTM (42.2 percent) 
and also the most often mentioned barrier (33.8 percent) to CDTM. CONCLUSIONS: 
Pharmacy directors feel CDTM is supported by hospital staff and has positive strate-
gic impact in facilitating the implementation of pharmacy services. These positive 
perceptions of CDTM have been maintained over the last decade.
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OBJECTIVES: To determine the optimal capacity and workflow processes of the 
Outpatient Surgery Center (OSC) for a rural hospital based on the future demand, 
redesigned care processes, and current available technologies using the Discrete Event 
Simulation (DES) method. METHODS: Planning for health care delivery services is 
extremely complex due to the involvement and interactions of people, facility, pro-
cess, and technology. Making data-driven decisions, while customizing care to the 
needs of individual patients and family, is critical to efficiently delivering patient-
centered care. We employed the Discrete Event Simulation (DES) method to optimize 
the future bed capacity based on the projected demands. Workflow improvements, 
that were necessary to meet efficiency optimization and desired patient experience 
for future success of the OSC, were also identified. The planning team developed a 
future state floor plan that met the needs of the patients and staff based on a set of 
assumptions. Locations of rooms, resources, and optimal workflows were determined 
through data collected from observations and time studies of outpatient surgery 
holding rooms, treatment rooms, and operating rooms. Patient tracks were modeled 
within the simulation from the collected data which generated a real-world view of 
patient flow through the system. RESULTS: The simulation allowed for the utilization 
of current time study data to determine how changes impacted the future output 
metrics and care processes using a new floor plan. By running the simulations with an 
improved room turnover process and an increased patient volume, it was concluded 
that the optimal number of outpatient surgery beds was 17 instead of the 22 beds 
that were recommended by the marketing and planning department. CONCLUSIONS: 
The optimal bed capacity allows for potential future growth and would maximize 
room utilization by limiting the number of idle rooms (idle rooms waste healthcare 
resources) while providing the best patient experience.
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OBJECTIVES: The objective was to establish whether the level of education of the 
head of household influences ownership and use of mosquito treated nets among 
household members. Ownership and use of treated nets has been shown to be an 
effective method of reducing malaria transmission. Scaling up the use of treated 
nets in order to protect < 5 years children and pregnant women against malaria 
was one of the targets set by African Heads of States in Abuja Declaration in 2000. 
In Kenya, various mechanisms including mass campaigns and distribution of 
nets in hospital clinics have been used to make the nets accessible. METHODS: 
A household baseline survey was carried out in Western Kenya in which 1620 
heads of households were interviewed. A total of 8848 people among them heads 
of households, spouses, children by birth, children by relationship, grand-chil-
dren, house-help and other relatives in the household were included in the study. 
Heads of households were asked whether they owned treated mosquito nets and 
state the number of household members by relationship that slept under treated 
mosquito nets the night preceding the survey. RESULTS: The study showed that 
98 % (1584/1620) of the heads of households interviewed, 94% (1489) said they 
owned nets. Ninety percent (82/91) had no education; primary education, 92 
%( 1240/1348); secondary education, 93 %(134/144); and tertiary education and 
above, 100%(26/26). Similar trend was observed also in the use of treated mosquito 
nets. CONCLUSIONS: It was concluded that the level of education does influence 
ownership and use of mosquito nets among members of households .The pro-
portion of ownership and use of treated mosquito nets increased as the level of 
education increased. However, there is need to investigate the effect of age, main 
source of income and relationship to head of household among other factors in 
order to get a better understanding.
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OBJECTIVES: The objective of the analysis was to compare trends of single versus 
multiple technology appraisals (STA versus MTA) recommendations for new tech-
nologies conducted by NICE. Analysis was also conducted for products with European 
Union (EU) orphan designation. Further analysis was conducted to identify any dis-
ease areas that could be particularly challenging for companies planning a European 
launch of any new products, aiming to support planning for sequencing across the 
EU. METHODS: A longitudinal database containing all technology appraisal guidance 
published by NICE since the formation of the organization was analyzed. Analysis 
of products by disease area was conducted by classification into British National 
Formulary (BNF) categories. All published guidance was included thus reviews 
of technology appraisals, which overwrite earlier guidance, were not accounted 
for. RESULTS: In 2000-2007, the ratio of guidance published for MTAs to STAs was 
3:1 (54 versus 17). However, this ratio was reversed in 2008-2014, when guidance was 
published for 46 MTAs and 132 STAs. In 2009, 92% of STA guidance included positive 
or restricted recommendation (n= 12), decreasing to a historical low of 52% in 2013 
(n= 27) and increasing to 85% in 2014 (n= 20). 50% of recommendations for orphan 
products were positive or restricted in 2011 and 2013 (n= 6) but 100% were positive 
or restricted in 2012 and 2014 (n= 3). The overall recommendation rate is lower for 
orphan products than no-orphan products (67% versus 73%). Malignant disease and 
immunosuppression treatments were the most common STAs but had the second 
lowest recommendation rate (59%, n= 71). Cardiovascular treatments were most con-
sistently recommended (100%, n= 19). CONCLUSIONS: A decreasing proportion of 
appraisals include multiple technologies. There have been substantial variations in 
annual recommendations from STAs, possibly due to the choice of appraisal commit-
tee and evidence review group, which makes it very challenging for manufacturers 
to predict likely outcomes.
PHP137
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OBJECTIVES: Data published by the Office for Health Economics in 2011 showed 
rejection from the SMC was more likely for orphan than for non-orphan prod-
ucts. Following a review of the SMC in 2012, the process for appraising end-of-life, 
orphan and ultra-orphan drugs was modified to facilitate greater access for patients 
in Scotland. We analyze if the revised SMC process has been successful in provid-
ing more positive recommendations for orphan products and which factors may 
influence the decision. METHODS: Analyses were based on a validated, longitudi-
nal database of all recommendations from 2002 to 2014. Products with a European 
Orphan designation were analysed. SMC recommendations following full submission, 
resubmission or abbreviated submission were reviewed and sub divided into British 
National Formulary (BNF) category. RESULTS: In 2002-2014, there were 8 abbreviated 
submissions to the SMC for orphan products, 68 full submissions and 25 resubmis-
sions. The positive recommendations rate (with or without restriction) from 2002-2013 
was 53% (n= 92); in 2014 this recommendation rate increased to 89% (n= 9). Up to 2013, 
malignant disease and immunosuppressive treatments accounted for 43% of the 
published guidance of orphan products with a recommendation rate of 50% (n= 40); 
in 2014 this improved to 80% (n= 5). Cardiovascular treatments have a high recom-
mendation rate of 92% (n= 13) but treatments for musculoskeletal and joint diseases 
have the lowest success with all three submissions receiving negative recommenda-
tion. In 2013, evidence for 7 orphan products was not submitted to the SMC within 
the required 3 months of license thus received automatic negative recommenda-
tion, however, this reduced to only one non-submission in 2014. CONCLUSIONS: The 
SMC recommendation rate for orphan products, particularly malignant disease and 
immunosuppressive drugs, has improved from 2013 to 2014 suggesting the revised 
SMC appraisal process may be more effective in enabling the SMC to provide positive 
recommendations for orphan products.
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OBJECTIVES: Since formation in 2002, the Scottish Medicines Consortium (SMC) has 
evaluated 608 health technology assessment (HTA) submissions of new medicines for 
use in Scotland. They have, therefore, reviewed more clinical and cost-effectiveness 
evidence for medicines than any other HTA organization in the world. Trends in 
SMC guidance were analysed to provide insights on likely recommendations of new 
products as manufacturers navigate the UK market. METHODS: All analyses were 
based on a validated, longitudinal database of all published guidance from 2002 to 
2014. SMC recommendations following full submission, resubmissions or abbreviated 
submissions were reviewed and then subdivided into British National Formulary (BNF) 
category. RESULTS: From 2002 to 2014, the SMC has published guidance following 608 
full submissions, 232 abbreviated submissions, 157 non-submissions, 158 resubmis-
sions and 5 Independent review panels. The proportion of products not recommended 
has fallen from 40% in 2007 (n= 98) to only 17% in 2014 (n= 84). Products falling into the 
malignant disease and immunosuppression BNF category were the most common 
submission to the SMC (20% of submissions, n= 197) with an approval rate steadily 
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OBJECTIVES: To describe reporting rates of gender-specific safety outcomes 
for new molecular entity (NME) drugs approved from the US Food and Drug 
Administration (US FDA) between 2009 and 2013 METHODS: New drug applica-
tion (NDA) files for all NME drugs that were approved for systemic use in men and 
women were surveyed from the US FDA database. Specific reviews and key word 
searches were made for descriptions or tabulation of gender-specific inferential 
statistics on the drug safety section. The rates of inclusion of explicit descriptions 
or reports of statistical significance were calculated. RESULTS: Of all 457 approved 
drugs during the study period, 118 NMEs were included for the evaluation. Of 
those, 8 NMEs and 13 NMEs were excluded due to gender specific indications or 
non-systemic route of administration, respectively, thereby remaining 97 NME 
drugs were further reviewed. On average, gender-specific safety outcome descrip-
tions were included in 74.2% (72/97) of the reviews. Gender-specific statistical 
significance was reported in 13% of the reviews. Format of the outcome descrip-
tions was inconsistent varying from statement in the body text to table without 
descriptions. CONCLUSIONS: About one in four NDA reviews for NMEs was lacking 
sufficient descriptions on gender-specific safety outcomes and the format of the 
safety outcome reports by gender was inconsistent.
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OBJECTIVES: Little guidance exists for healthcare professionals on how to evaluate 
and use CER studies with new unfamiliar designs or methods. To fill this gap, the 
CER Collaborative (AMCP, IPSOR, and NPC) developed task force reports and on-line 
tools. The aim of this study was to determine if a multi-media continuing educa-
tion (CE) program, largely derived from task-force reports and related online CER 
Collaborative tools, improved learner ability and confidence to assess CER studies 
for use in real-world decision-making. METHODS: Twenty healthcare profession-
als registered for a 19-hour, ACPE-approved CER Certificate Program (CCP) which 
included five self-paced, online modules and case studies: prospective and retro-
spective observational studies, indirect treatment comparisons, models, and syn-
thesizing information from studies with various designs. A final live workshop was 
conducted to enhance learner skills through case presentation and peer critique. 
After CCP completion, learners assessed their ability to evaluate CER studies using a 
Likert scale (1= strongly disagree, 5= strongly agree). RESULTS: In the first cohort of 
learners, 18 (90%) completed the program on schedule. Significant improvement in 
self-reported ability to evaluate CER study design on their relevance and credibility 
ranged from 29.17% (CI 18.50 - 39.83) to 61.76% (CI 49.08 – 74.45) at program comple-
tion. Learners indicated high confidence in their CER evidence assessment abilities 
(mean score 4.17; CI 3.93 – 4.40). CONCLUSIONS: As new or unfamiliar CER study 
designs and analyses become available, there will be an increasing need for clini-
cians and other decision-makers to understanding how to assess the relevance and 
credibility of CER studies to inform decision-making. The CER Certificate Program, 
was associated with improved healthcare decision-makers’ self-reported ability to 
evaluate CER and apply it for use in decision-making.
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OBJECTIVES: A review of the literature was conducted to determine whether there 
is an appropriate definition for market access. The original perception was that 
it relates to securing market authorization, as well as enabling prescribing of the 
product. A working definition for pharmaceutical market access was proposed as 
“a process of enabling patient access to pharmaceutical products, not only through 
gaining regulatory approval, but also through gaining an acceptable optimal price 
and reimbursement status to manufacturers and payers.” The objective of this 
survey was to determine how appropriate the proposed definition is by compar-
ing it to definitions proposed by differing professionals within the healthcare 
industry. METHODS: A review of the literature was undertaken, followed by the 
development of a questionnaire aimed at eliciting the various determinants of 
pharmaceutical market access, both from the patient and payer perspectives. This 
survey was administered to professionals in three settings involving ISPOR European 
Congress, EMAUD educational course, and a pharmaceutical company, with forty 
eight, forty five, and seventeen respondents, respectively. The respondents were 
categorized as belonging to: academia, pharmaceutical industry, healthcare pro-
fession, policy maker/Health Technology Assessment Agency (payer), and consul-
tancy. Responses were recorded verbatim, and then coded by the interviewers to 
aid analysis. RESULTS: The survey suggested there is an inadequate understanding 
of market access, and this is independent of the professional background of the 
respondent. Furthermore, there is not a consistent agreement as to what factors 
influence the successful development and commercialization of pharmaceutical 
products. CONCLUSIONS: Successful market access of pharmaceutical products 
requires a wider understanding of the role of patients and payers in the develop-
ment and commercialization by all stakeholders in the healthcare delivery system. 
Further research is needed into this field as it has important health policy implica-
tions for patient care.
